"A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)" by M. Ernstoff

Selected Works of Walter J. Urba, MD, PhD

Article

A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)

Journal of Clinical Oncology (2005)

M. Ernstoff, Loyola University Chicago
C. Carrillo
W. Urba, Providence Portland Medical Center
L. Flaherty, Loyola University Chicago
J. Clark, Loyola University Chicago
J. Dutcher, New York Medical College
K. Margolin, Seattle Cancer Care Alliance
M. Atkins, Indiana University
J. A. Sosman

Link

Disciplines

Physical Therapy,
Medicine and Health Sciences,
Surgery and
Oncology

Publication Date

January 6, 2005

DOI

10.1200/jco.2005.23.16_suppl.7504

Citation Information

M. Ernstoff, C. Carrillo, W. Urba, L. Flaherty, et al.. "A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)" Journal of Clinical Oncology Vol. 23 (2005) p. 7504 - 7504
Available at: http://works.bepress.com/walter-urba/202/